77 - SARS-CoV-2 Variants: Preparing for the Inevitable

Thursday, October 20, 2022

1:45 PM – 3:00 PM US ET

Location: 146 ABC

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Emily Erbelding, MD

Director, Division of Microbiology and Infectious Disease NIAID
National Institutes of Health
Rockville, MD, United States

Disclosure(s): No financial relationships to disclose
Christine Johnston, MD, MPH

Associate Professor
Medicine
University of Washington
Seattle, Washington, United States

Disclosure(s): Abbvie: Advisor/Consultant (Terminated); Gilead Biosciences: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); GSK: Advisor/Consultant (Ongoing); UpToDate Wolters Kluwer Health: Royalties (Ongoing)

Faculty(s)

Elodie Ghedin, PhD

Senior Investigator
National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), MD, United States

Disclosure(s): No financial relationships to disclose

Slides
Amy Kirby, PhD MPH

National Wastewater Surveillance System Lead
Centers for Disease Control and Prevention
Atlanta, GA, United States

Disclosure(s): No financial relationships to disclose

Slides
Angela Branche, MD

Associate Professor of Medicine
Medicine
University of Rochester
Rochester, New York, United States

Disclosure(s): AzurXBiopharma: Board Member (Terminated); Cyanvac: Grant/Research Support (Ongoing); GSK Vaccines: Advisor/Consultant (Terminated); Janssen Pharmaceutica: Advisor/Consultant (Ongoing); Merck & Co., Inc.: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing)

Slides

Disclosure(s):

Emily Erbelding, MD: No financial relationships to disclose

Christine Johnston, MD, MPH: Abbvie: Advisor/Consultant (Terminated); Gilead Biosciences: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); GSK: Advisor/Consultant (Ongoing); UpToDate Wolters Kluwer Health: Royalties (Ongoing)

Elodie Ghedin, PhD: No financial relationships to disclose

Amy E. Kirby, PhD MPH: No financial relationships to disclose

Angela R. Branche, MD: AzurXBiopharma: Board Member (Terminated); Cyanvac: Grant/Research Support (Ongoing); GSK Vaccines: Advisor/Consultant (Terminated); Janssen Pharmaceutica: Advisor/Consultant (Ongoing); Merck & Co., Inc.: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe how SARS-CoV-2 has evolved throughout the pandemic and how this information can be used to predict future evolution;
discuss how wastewater monitoring may be utilized for early identification and tracking of novel variants;
identify strategies to study SARS-CoV-2 vaccine combinations to maximize immunologic memory to variants

Presentations:

1:45 PM – 2:10 PM US ET

Evolving Variants: Can We Predict the Future?
Speaker: Elodie Ghedin, PhD – National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH)
2:10 PM – 2:35 PM US ET

What’s in the Wastewater? How Wastewater Monitoring Can Shape Pandemic Response
Speaker: Amy E. Kirby, PhD MPH – Centers for Disease Control and Prevention
2:35 PM – 3:00 PM US ET

Staying a Step Ahead: Can Vaccines Keep Up With Variants?
Speaker: Angela R. Branche, MD – University of Rochester